- Report
- February 2024
- 70 Pages
Latin America
From €4213EUR$4,750USD£3,654GBP
- Report
- February 2024
- 150 Pages
Global
From €4213EUR$4,750USD£3,654GBP
- Report
- August 2023
- 70 Pages
Latin America
From €4213EUR$4,750USD£3,654GBP
- Report
- August 2023
- 150 Pages
North America
From €4213EUR$4,750USD£3,654GBP
- Report
- August 2023
- 70 Pages
Africa, Middle East
From €4213EUR$4,750USD£3,654GBP
- Report
- August 2023
- 70 Pages
South Korea
From €4213EUR$4,750USD£3,654GBP
- Report
- August 2024
- 178 Pages
Global
From €2217EUR$2,500USD£1,923GBP
- Report
- June 2025
- 250 Pages
Canada
From €2474EUR$2,789USD£2,146GBP
- Report
- August 2024
- 150 Pages
Global
From €2474EUR$2,789USD£2,146GBP
- Report
- March 2025
- 50 Pages
Kenya
From €532EUR$600USD£462GBP
- Report
- March 2025
- 50 Pages
Nigeria
From €532EUR$600USD£462GBP
- Report
- March 2025
- 50 Pages
Egypt
From €532EUR$600USD£462GBP
From €532EUR$600USD£462GBP
- Report
- March 2025
- 50 Pages
Greece
From €532EUR$600USD£462GBP
- Report
- March 2025
- 50 Pages
Finland
From €532EUR$600USD£462GBP
- Report
- March 2025
- 50 Pages
Denmark
From €532EUR$600USD£462GBP
- Report
- March 2025
- 50 Pages
Norway
From €532EUR$600USD£462GBP
- Report
- March 2025
- 50 Pages
Austria
From €532EUR$600USD£462GBP
- Report
- March 2025
- 50 Pages
Ireland
From €532EUR$600USD£462GBP
- Report
- March 2025
- 50 Pages
Sweden
From €532EUR$600USD£462GBP

The Sodium Dependent Glucose Co Transporter 2 (SGLT2) market is a subset of the Endocrine and Metabolic Disorders Drugs market. SGLT2 inhibitors are a class of drugs used to treat type 2 diabetes, a chronic condition in which the body does not produce enough insulin or is unable to use insulin effectively. These drugs work by blocking the reabsorption of glucose in the kidneys, allowing it to be excreted in the urine. This helps to reduce blood glucose levels and improve glycemic control.
The SGLT2 market is highly competitive, with several major pharmaceutical companies offering products. These include AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen Pharmaceuticals, Merck, Novo Nordisk, and Sanofi. Each company offers a range of products, including both branded and generic versions. Show Less Read more